Potential impact of the bivalent rLP2806vaccine on Neisseria meningitidis carriage and invasive serogroup B disease

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 3, 2013, Pages 471-479

  Anderson, Annaliesa S ^a   Hao, Li ^a   Jiang, Qin ^a   Harris, Shannon L ^a   Jones, Thomas R ^a   Perez, John L ^a   York, Laura ^a   Eiden, Joseph ^a   Jansen, Kathrin U ^a  

^a Pfizervaccine Research   (United States)

Author keywords

Factor H binding protein; Herd protection; Meningococcal carriage; Meningococcalvaccines; Neisseria meningitidis serogroup B

Indexed keywords

BIVALENT RLP2806 VACCINE; FACTOR H BINDING PROTEIN A; FACTOR H BINDING PROTEIN B; MENINGOCOCCAL SEROGROUP B VACCINE; MENINGOCOCCUS VACCINE; PROTEIN VARIANT; UNCLASSIFIED DRUG; BACTERIAL ANTIGEN; BACTERIAL PROTEIN; BACTERIUM ANTIBODY; FACTOR H-BINDING PROTEIN, NEISSERIA MENINGITIDIS; RECOMBINANT PROTEIN; RECOMBINANT VACCINE;

ADOLESCENT; ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; BACTERIAL STRAIN; BACTERIAL TRANSMISSION; BACTERICIDAL ACTIVITY; BACTERIUM CARRIER; BACTERIUM ISOLATE; CONFERENCE PAPER; DRUG EFFICACY; HUMAN; INFANT; MAJOR CLINICAL STUDY; MENINGOCOCCAL SEROGROUP B DISEASE; MENINGOCOCCOSIS; MICROBIAL ACTIVITY; NEISSERIA MENINGITIDIS; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FAMILY; VACCINE PRODUCTION; BACTEREMIA; BLOOD; FEMALE; GENETICS; HETEROZYGOTE; IMMUNOLOGY; MALE; MENINGOCOCCAL INFECTIONS; NEWBORN; PREVENTION AND CONTROL; SERUM BACTERICIDAL ACTIVITY; YOUNG ADULT;

ADOLESCENT; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTEREMIA; BACTERIAL PROTEINS; BLOOD BACTERICIDAL ACTIVITY; CARRIER STATE; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS, SEROGROUP B; RECOMBINANT PROTEINS; VACCINES, SYNTHETIC; YOUNG ADULT;

EID: 84874691273     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.23222     Document Type: Conference Paper

References (41)

1. Stephens DS. Biology and pathogenesis of the evolutionarily successful, obligate human bacterium Neisseria meningitidis.vaccine 2009; 27(Suppl 2):B71-7; PMID:19477055; http://dx.doi.org/10.1016/j.vaccine. 2009.04.070.
2. Bidmos FA, Neal KR, Oldfield NJ, Turner DP, Ala'Aldeen DA, Bayliss CD. Persistence, replacement, and rapid clonal expansion of meningococcal carriage isolates in a 2008 university student cohort. J Clin Microbiol 2011; 49:506-12; PMID:21123536; http://dx.doi.org/10.1128/JCM.01322-10.
3. Jounio U, Saukkoriipi A, Bratcher HB, Bloigu A, Juvonen R, Silvennoinen-Kassinen S, et al. Genotypic and phenotypic characterization of carriage and invasive disease isolates of Neisseria meningitidis in Finland. J Clin Microbiol 2012; 50:264-73; PMID:22135261; http://dx.doi.org/10.1128/JCM. 05385-11.
4. Girard MP, Preziosi MP, Aguado MT, Kieny MP. A review ofvaccine research and development: meningococcal disease.vaccine 2006; 24:4692-700; PMID:16621189; http://dx.doi.org/10.1016/j.vaccine. 2006.03.034.
5. Granoff DM, Harrison LH, Borrow R. Meningococcalvaccines. In: Plotkin SA, Orenstein WA, Offit P, eds.vaccines. Philadelphia: Saunders Elsevier, 2008:399-434.
6. Centers for Disease Control and Prevention. Active Bacterial Core Surveillance (ABCs) Report, Emerging Infections Program Network, Neisseria meningitidis, 2009. Available via the Internet: http://www.cdc.gov/abcs/reports- findings/survreports/mening09.pdf. 2010.
7. European Centre for Disease Prevention and Control. Annual Epidemiological Report 2011. Reporting on 2009 surveillance data and 2010 epidemic intelligence data. Stockholm: ECDC. http://ecdc.europa. eu/en/publications/Publications/1011-SUR-Annual-Epidemiological-Report-on- Communicable-Diseases-in-Europe.pdf 2011.
8. Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease.vaccine 2009; 27(Suppl 2):B51-63; PMID:19477562; http://dx.doi.org/10. 1016/j.vaccine.2009.04.063.
9. Zollinger WD, Boslego J. Immunologic Methods for Diagnosis of Infections by Gram-Negative Cocci. In: Rose NR, ed. Manual of clinical laboratory immunology. Washington, DC: ASM Press, 1997:473-83.
10. Germinario C, Tafuri S, Napoli C, Montagna MT, Balducci MT, Fortunato F, et al. Young-adult carriers of Neisseria meningitidis in Puglia (Italy): will the pattern of circulating meningococci change following the introduction of meningococcal serogroup C conjugatevaccines? Hum Vaccin 2010; 6:1025-7; PMID:21150271; http://dx.doi.org/10.4161/hv.6.12.13145.
11. Yazdankhah SP, Kriz P, Tzanakaki G, Kremastinou J, Kalmusova J, Musilek M, et al. Distribution of serogroups and genotypes among disease-associated and carried isolates of Neisseria meningitidis from the Czech Republic, Greece, and Norway. J Clin Microbiol 2004; 42:5146-53; PMID:15528708; http://dx.doi.org/10. 1128/JCM.42.11.5146-5153.2004.
12. Christensen H, May M, Bowen L, Hickman M, Trotter CL. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10:853-61; PMID:21075057; http://dx.doi.org/10.1016/S1473-3099(10)70251-6.
13. Trotter CL, Ramsay ME. Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugatevaccines. FEMS Microbiol Rev 2007; 31:101-7; PMID:17168998; http://dx.doi.org/10.1111/j.1574- 6976.2006.00053.x. (Pubitemid 46058826)
14. Maiden MC, Stuart JM; UK Meningococcal Carraige Group. Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet 2002; 359:1829-31; PMID:12044380; http://dx.doi.org/10.1016/ S0140-6736(02)08679-8.
15. Ramsay ME, Andrews NJ, Trotter CL, Kaczmarski EB, Miller E. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ 2003; 326:365-6; PMID:12586669; http://dx.doi.org/10.1136/bmj.326. 7385.365. (Pubitemid 36241472)
16. Campbell H, Andrews N, Borrow R, Trotter C, Miller E. Updated postlicensure surveillance of the meningococcal C conjugatevaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity. Clinvaccine Immunol 2010; 17:840-7; PMID:20219881; http://dx.doi.org/10.1128/CVI.00529-09.
17. Centers for Disease Control and Prevention. Summary of notifiable diseases -United States, 2009. MMWR Morb Mortal Wkly Rep 2011; 58:1-100; PMID:21566560.
18. UK Health Protection Agency. Meningococcal Reference Unit: Isolates of Neisseria menengitidis; England and Wales, by serogroup & calendar year, 1998-2009. http://www.hpa.org.uk/web/HPAweb&HPAwebStandard/HPAweb-C/ 1272032921946?pri 2010.
19. Soriano-Gabarró M, Wolter J, Hogea C, Vyse A. Carriage of Neisseria meningitidis in Europe: a review of studies undertaken in the region. Expert Rev Anti Infect Ther 2011; 9:761-74; PMID:21905785; http://dx.doi.org/10. 1586/eri.11.89.
20. Marsh JW, Shutt KA, Pajon R, Tulenko MM, Liu S, Hollick RA, et al. Diversity of factor H-binding protein in Neisseria meningitidis carriage isolates.vaccine 2011; 29:6049-58; PMID:21704667; http://dx.doi.org/10.1016/j. vaccine.2011.06.025.
21. Núñez N, Martínez I, Izquierdo L, Álvarez N, López O. Portadores de Neisseria meningitidis y Neisseria lactamica en tres grupos de edades diferentes. VacciMonitor 2007; 16:1-6.
22. Parodi V, Allende F, Torres E, Macedo M, Maglione R, Algorta G. Portadores de Neisseria meningitidis en una poblaci6n de Montevideo. Rev Med Uruguay 1998; 14:221-5.
23. Ibarz-Pavón AB, Lemos AP, Gorla MC, Regueira M, Gabastou JM; SIREVA Working Group II. Laboratory-based surveillance of Neisseria meningitides isolates from disease cases in Latin American and Caribbean countries, SIREVA II 2006-2010. PLoS One 2012; 7:e44102; PMID:22952888; http://dx.doi.org/10.1371/ journal.pone.0044102.
24. Bruge J, Bouveret-Le Cam N, Danve B, Rougon G, Schulz D. Clinical evaluation of a group B meningococcal N-propionylated polysaccharide conjugatevaccine in adult, male volunteers.vaccine 2004; 22:1087-96; PMID:15003635; http://dx.doi.org/10.1016/j.vaccine.2003.10.005. (Pubitemid 38296650)
25. Tondella ML, Popovic T, Rosenstein NE, Lake DB, Carlone GM, Mayer LW, et al.; The Active Bacterial Core Surveillance Team. Distribution of Neisseria meningitidis serogroup B serosubtypes and serotypes circulating in the United States. J Clin Microbiol 2000; 38:3323-8; PMID:10970378.
26. Anderson AS, Jansen KU, Eiden J. New frontiers in meningococcalvaccines. Expert Revvaccines 2011; 10:617-34; PMID:21604983; http://dx.doi.org/10.1586/ erv.11.50.
27. Murphy E, Andrew L, Lee KL, Dilts DA, Nunez L, Fink PS, et al. Sequence diversity of the factor H binding proteinvaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J Infect Dis 2009; 200:379-89; PMID:19534597; http://dx.doi.org/10.1086/600141.
28. Schneider MC, Exley RM, Chan H, Feavers I, Kang YH, Sim RB, et al. Functional significance of factor H binding to Neisseria meningitidis. J Immunol 2006; 176:7566-75; PMID:16751403. (Pubitemid 43849060)
29. Madico G, Welsch JA, Lewis LA, McNaughton A, Perlman DH, Costello CE, et al. The meningococcalvaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J Immunol 2006; 177:501-10; PMID:16785547.
30. Pajon R, Beernink PT, Harrison LH, Granoff DM. Frequency of factor H-binding protein modular groups and susceptibility to cross-reactive bactericidal activity in invasive meningococcal isolates.vaccine 2010; 28:2122-9; PMID:20044056; http://dx.doi.org/10.1016/j.vaccine.2009.12.027.
31. Fletcher LD, Bernfield L, Barniak V, Farley JE, Howell A, Knauf M, et al.vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect Immun 2004; 72:2088-100; PMID:15039331; http://dx.doi.org/10.1128/IAI.72.4.2088- 2100.2004. (Pubitemid 38419922)
32. Zhu D, Zhang Y, Barniak V, Bernfield L, Howell A, Zlotnick G. Evaluation of recombinant lipidated P2086 protein as avaccine candidate for group B Neisseria meningitidis in a murine nasal challenge model. Infect Immun 2005; 73:6838-45; PMID:16177362; http://dx.doi.org/10.1128/IAI.73.10.6838-6845.2005.
33. Jiang HQ, Hoiseth SK, Harris SL, McNeil LK, Zhu D, Tan C, et al. Broadvaccine coverage predicted for a bivalent recombinant factor H binding protein basedvaccine to prevent serogroup B meningococcal disease.vaccine 2010; 28:6086-93; PMID:20619376; http://dx.doi.org/10.1016/j.vaccine.2010.06.083.
34. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med 1969; 129:1307-26; PMID:4977280; http://dx.doi.org/10.1084/jem.129.6.1307.
35. Borrow R, Carlone GM, Rosenstein N, Blake M, Feavers I, Martin D, et al. Neisseria meningitidis group B correlates of protection and assay standardization -international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005.vaccine 2006; 24:5093-107; PMID:16838413; http://dx.doi.org/10.1016/j.vaccine.2006.03.091.
36. Zlotnick G, Hoiseth SK, Jiang HQ, Murphy E, Andrew L, McNeil LK, et al. Epidemiology of the serogroup B Neisseria meningitidis (MnB) factor H binding protein in Strains Samples from Spain and Germany in the years 2001-2006 (poster P045). Presented at the 10th Meeting of the European Meningococcal Disease Society; Manchester, UK 2009.
37. Ala'aldeen DA, Flint M, Oldfield NJ, Omer SA, McNeil LK, Jiang Q, et al. Human antibody responses to the meningococcal factor H binding protein (LP2086) during invasive disease, colonization and carriage.vaccine 2010; 28:7667-75; PMID:20875489; http://dx.doi.org/10.1016/j.vaccine.2010.09.038.
38. McNeil LK, Murphy E, Zhao XJ, Guttmann S, Harris SL, Scott AA, et al. Detection of LP2086 on the cell surface of Neisseria meningitidis and its accessibility in the presence of serogroup B capsular polysaccharide.vaccine 2009; 27:3417-21; PMID:19200847; http://dx.doi.org/10.1016/j.vaccine.2009.01. 075.
39. Richmond PC, Marshall HS, Nissen MD, Jiang Q, Jansen KU, Garcés-Sánchez M, et al.; 2001 Study Investigators. Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis 2012; 12:597-607; PMID:22569484; http://dx.doi.org/10.1016/S1473-3099(12)70087-7.
40. Marshall H, Richmond P, Nissen M, Jiang Q, Anderson AS, Jansen KU, et al. A phase 1/2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086vaccine in healthy adults (poster P046). Presented at: 11th European Meningococcal Disease Society Congress, Ljubljana, Slovenia 2011.
41. Masignani V, Comanducci M, Giuliani MM, Bambini S, Adu-Bobie J, Arico B, et al. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J Exp Med 2003; 197:789-99; PMID:12642606; http://dx.doi.org/10.1084/jem.20021911. (Pubitemid 36350873)